Since the increased level of serum FGF21 in clinical studies has been found to be correlated with the degree of fibrosis and prognosis of fibrotic disease, FGF21 is expected to become a new biomarker for the evaluation of fibrosis diseases and provide a reference for clinical diagnosis and treatment. The gene discussed is FGF21; the disease is fibrosis.